Tag Archives: bbT4015

Thoughts on Regeneron Acquiring 2seventy bio’s Pipeline; How Could Regeneron Leverage its New Cell Therapy Pipeline?

On Tuesday, January 30, Regeneron announced (press release) the formation of Regeneron Cell Medicines based on an asset purchase agreement to acquire full development and commercialization rights to 2seventy bio’s pipeline, along with the clinical manufacturing capabilities, and related platform technologies.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account. Log in now

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

If you receive our email blasts, you already have an account. Log in now

Context counts when making decisions.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma Revenue Decreases Significantly; bbT4015 IND on Track for YE 2023; JW Tx to Initiate JWTCR001’s IIT by YE 2023; 2seventy Bio’s Q3 2023 Earnings Call

On Tuesday, November 14, 2seventy bio held its Q3 2023 earnings call (press release / webcast) acknowledging Abecma’s (BMS / 2seventy’s BCMA CAR-T) decline in US sales while confirming milestones for its preclinical cell therapy programs in solid tumors. Below, Celltelligence provides insights on the causes behind Abecma’s revenue decrease while discussing the company’s preclinical solid tumor pipeline.

About The Author

The Celltelligence Team

Content Leads & Contributors

If you receive our email blasts, you already have an account. Log in now

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

If you receive our email blasts, you already have an account. Log in now

Context counts when making decisions.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

2seventy bio Announces Strategic Restructuring and Pipeline Reprioritization; Abecma’s US Revenue Guidance Lowered; Nick Leschly to Resign as CEO; Company to Expand Strategic Partnership with JW Tx

On September 12, 2023, 2seventy bio held a conference call (webcast / press release) announcing the strategic restructuring of the company’s business operations and R&D model. Measures include a 40% workforce reduction and a pipeline reprioritization and are driven by a projected decrease in Abecma’s (BMS / 2seventy BCMA CAR-T) revenue for 2023. Additionally, the company disclosed Nick Leschly’s decision to step down as CEO. On the same day, 2seventy announced the expansion of its collaboration with JW Tx adding 2 new assets from its pipeline: a solid tumor targeting TCR-T and a CAR-T for autoimmune diseases (press release). Below, Celltelligence provides insights on 2seventy’s new Abecma revenue projections for 2023 and the collaborative R&D model that the company aims to implement for its pipeline.

About The Author

The Celltelligence Team

Content Leads & Contributors

If you receive our email blasts, you already have an account. Log in now

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

If you receive our email blasts, you already have an account. Log in now

Context counts when making decisions.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma’s US Revenue Continues to Increase; DARIC33’s Data to Be Presented at ASGCT 2023; Manufacturing Capacity Ramping Up; 2seventy bio’s Q1 2023 Earnings Call Summary

On Wednesday, May 3, 2seventy bio held its Q1 2023 earnings call (press release) highlighting Abecma’s (BMS / 2seventy’s BCMA CAR-T) significant revenue increase. Moreover, management confirmed that early clinical data from DARIC33’s Ph1 PLAT-08 trial in r/r AML will be presented at ASGCT 2023 (May 16-20). Below, Celltelligence provides insights on 2seventy bio’s strategy to improve manufacturing capacity with a newly FDA-approved viral vector manufacturing suite, while discussing the main clinical milestones achieved by the assets in the pipeline.

About The Author

The Celltelligence Team

Content Leads & Contributors

If you receive our email blasts, you already have an account. Log in now

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

If you receive our email blasts, you already have an account. Log in now

Context counts when making decisions.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma’s sBLA Filing in ≥3L MM Remains on Track for Q1 2023; No Pipeline Updates; 2seventy bio Q4 2022 Earnings Summary; Gracell Acquires Patent Licenses from Seagen

On Thursday, March 16, 2seventy bio released its Q4 and FY 2022 financial results (press release) highlighting Abecma’s (BCMA CAR-T) increased US revenue. Additionally, management did not provide major milestone updates for 2023, with Abecma’s sBLA filing to the FDA for ≥3L MM still expected in Q1 2023. On the same day, Gracell reported (SEC Filing) a license agreement with Seagen, under which Gracell will have WW licenses to certain patents for clinical and preclinical research, as well as commercialization, of cell therapy products. Below, Celltelligence provides insights on Abecma’s potential market growth for 2023, while discussing the license agreement between Gracell and Seagen.